635309-85-2

Upstream product

• 819067-17-9 4-[2-((S)-5-Benzyloxy-4-hydroxy-pentanoylamino)-ethyl]-benzoic acid methyl ester 
• 635309-84-1 (R)-methyl 4-(2-(2-(hydroxymethyl)-5-oxopyrrolidin-1-yl)ethyl)benzoate 
• 32780-06-6 (5S)-5-(hydroxymethyl)-2-oxo-tetrahydrofuran 
• 32780-08-8 (5S)-5-[(benzyloxy)methyl]dihydrofuran-2(3H)-one 

Downstream Products

• 635310-50-8 methyl 4-(2-{(2R)-2-[(1E)-4-cyclohexyl-3-oxobytyl-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoate 
• 635310-48-4 methyl 4-(2-{(2R)-2-[(1E)-6-methoxy-3-oxohex-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoate 
• 635311-20-5 methyl-4-{2-{(2R)-2-[(1E)-7-methyl-3-oxooct-1-enyl]-5-oxopyrrolidin-1-yl}ethyl}benzoate 
• 635310-09-7 methyl 4-[2-((2R)-2-{(1E)-3-[1-(3-fluorophenyl)cyclopentyl]-3-oxoprop-1-enyl}-5-oxopyrrolidin-1-yl)ethyl]benzoate 
• 635311-18-1 methyl 4-{2-{(2R)-2-[(1E)-5-cyclopentyl-3-oxopent-1-enyl]-5-oxopyrrolidin-1-yl}ethyl}benzoate 
• 635310-74-6 methyl 4-{2-[(2R)-2-((1E,7S)-7-{[tert-butyl(dimethyl)silyl]oxy}-3-oxooct-1-enyl)-5-oxopyrrolidin-1-yl]ethyl}benzoate 
• 635310-69-9 methyl 4-{2-[(2R)-2-((1E,7R)-7-{[tert-butyl(dimethyl)silyl]oxy}-3-oxooct-1-enyl)-5-oxopyrrolidin-1-yl]ethyl}benzoate 
• 635310-63-3 methyl 4-(2-{(2R)-2-[(1E)-7-chloro-3-oxohept-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoate 
• 635310-60-0 methyl 4-(2-{(2R)-2-[(1E)-5-methyl-3-oxohex-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoate 
• 635310-58-6 methyl 4-(2-{(2R)-2-[(1E)-5,5-dimethyl-3-oxohex-1-enyl]-5-oxopyrrolidin-1-yl}ethyl)benzoate 
• 635310-56-4 methyl 4-[2-{(2R)-2-[(1E)-3-oxooct-1-en-7-ynyl]-5-oxopyrrolidin-1-yl}ethyl]benzoate 
• 635310-44-0 methyl 4-[2-((2R)-2-{(1E)-3-[1-(phenyl)cyclopentyl]-3-oxoprop-1-enyl}-5-oxopyrrolidin-1-yl)ethyl]benzoate 
• 635310-40-6 methyl 4-[2-((2R)-2-{(1E)-3-[1-(4-chlorophenyl)cyclobutyl]-3-oxoprop-1-enyl}-5-oxopyrrolidin-1-yl)ethyl]benzoate 
• 635310-36-0 methyl 4-[2-((2R)-2-{(1E)-3-[1-(4-methylphenyl)cyclopentyl]-3-oxoprop-1-enyl}-5-oxopyrrolidin-1-yl)ethyl]benzoate 

Relevant academic research and scientific papers

LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS

Disclosed herein are compounds of formula (I) wherein L1, L2, L3, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH

The present invention relates to novel bone compositions for locally delivering a therapeutic agent to the site of a bone defect. Therapeutic agents may promote repair of the bone defect and/or treat conditions or disorders such as pain, inflammation, cancer, and infection. The compositions include calcium phosphate cements and a demineralized bone matrix or a collagen sponge. The compositions are useful for implantation in a patient at the site of a bone defect.

LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS

Disclosed herein are compounds of formula (I) wherein L 1 , L 2 , L 3 , L 4 , R 1 , R 4 , R 5 , R 6 , and s are as defined in the specification. Compounds of formula (I) are EP 4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS

Disclosed herein are compounds of formula (I) wherein L1, L2, L3, R1, R4, R5, and R6 are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

Synthesis and evaluation of a γ-lactam as a highly selective EP2 and EP4 receptor agonist

γ-Lactam analogs (2) of EP4 receptor agonists were identified by substitution of the pyrazolidinone ring (1) with a pyrrolidinone ring. Several compounds (such as 2a, 2h) with high potency, selectivity and acceptable PK profiles were discovered. These were assessed in animal models of ovulation induction and bronchoconstriction.

Lactams as EP4 prostanoid receptor agonists. 3. Discovery of N-ethylbenzoic acid 2-pyrrolidinones as subtype selective agents

Two distinct synthetic schemes were applied to access heteroatom-containing α-chain lactams or lactams terminated as aryl acids. The latter lactams were devised using a pharmacophore for EP4 receptor activity. γ-Lactams were characterized for their prostanoid EP receptor affinities and EP 4 activity and found to be selective for the EP2 and EP4 receptors or selective for the EP4 subtype. Benzoic acid 17 displayed enhanced in vivo exposure relative to 3.

GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF

1,2-substituted 5-pyrrolidinone compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, renal dysfunction, an immune deficiency disorder, dry eye, ichthyosis, elevated intraocular pressure, sleep disorder, or gastric ulcer, inflammatory disorders and other diseases and disorders associated with the prostaglandin family of compounds.